Media Coverage

KindredBio equine ulcer product gets study thumbs up


May 30, 2018 - Animal Pharm
By Malcolm Flanagan
Animal Pharm
May 30, 2018


US pet therapeutics specialist Kindred Biosciences has reported a successful study for its pipeline candidate for the treatment of gastric ulcers in horses.

The San Francisco-based company announced positive results from its pilot field effectiveness study of KIND-014 for the treatment of equine gastric ulcers.

The randomized, single-blind, placebo-controlled, dose-ranging study enrolled 53 horses – 40 horses in three KIND-014 groups with different doses and dosing schedules, and 13 horses in a placebo group.

The objective of the study was to determine the effective dose of KIND-014 for the treatment of gastric ulcers in horses. At week three, the gastric ulcer resolution rates in all three KIND-014 groups were statistically significantly higher than the placebo group.

The company recently said its Mirataz (mirtazapine transdermal ointment) product is the first and only transdermal medication specifically developed and FDA-approved for the management of weight loss in cats. Weight loss in cats is a serious and potentially fatal condition. The company shares hit an all-time high following approval of the product.

Additionally, the firm's Zimeta (dypirone oral gel) product is expected to be the first FDA-approved product for the control of fever in horses, a significant unmet medical condition that affects millions of horses each year. 

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum